Terms: = Kidney tumors AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI
3839 results:
1. Totally retroperitoneal approach for robot-assisted nephroureterectomy with bladder cuff without repositioning.
Hattori Y; Yamamoto A; Nagoshi A; Fujiwara T; Kambe T; Igarashi A; Akagi N; Shibasaki N; Kawakita M; Yamasaki T
Asian J Endosc Surg; 2024 Jul; 17(3):e13317. PubMed ID: 38692582
[TBL] [Abstract] [Full Text] [Related]
2. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
3. All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980-2018).
Biggeri A; Stoppa G; Facciolo L; Fin G; Mancini S; Manno V; Minelli G; Zamagni F; Zamboni M; Catelan D; Bucchi L
Environ Health; 2024 Apr; 23(1):42. PubMed ID: 38627679
[TBL] [Abstract] [Full Text] [Related]
4. Label-Free SERS of Urine Components: A Powerful Tool for Discriminating Renal Cell Carcinoma through Multivariate Analysis and Machine Learning Techniques.
Buhas BA; Toma V; Beauval JB; Andras I; Couți R; Muntean LA; Coman RT; Maghiar TA; Știufiuc RI; Lucaciu CM; Crisan N
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612705
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function.
Karaboyun K; İriağaç Y; Çavdar E; Avci O; Şeber ES
J Cancer Res Ther; 2024 Jan; 20(1):144-149. PubMed ID: 38554312
[TBL] [Abstract] [Full Text] [Related]
6. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
7. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract] [Full Text] [Related]
8. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis.
Huang RS; Chow R; Chopade P; Mihalache A; Hasan A; Boldt G; Glicksman R; Simone CB; Lock M; Raman S
Radiother Oncol; 2024 May; 194():110216. PubMed ID: 38462092
[TBL] [Abstract] [Full Text] [Related]
9. Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study.
Kollerits B; Gruber S; Steinbrenner I; Schwaiger JP; Weissensteiner H; Schönherr S; Forer L; Kotsis F; Schultheiss UT; Meiselbach H; Wanner C; Eckardt KU; Kronenberg F;
BMC Cancer; 2024 Mar; 24(1):320. PubMed ID: 38454416
[TBL] [Abstract] [Full Text] [Related]
10. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract] [Full Text] [Related]
11. Perioperative Complications of Single-Port and Multiport Robotic Radical Prostatectomy: A Single Institutional Comparison Analysis.
Soputro NA; Chavali JS; Ramos-Carpinteyro R; Mikesell C; Pedraza AM; Kaouk JH
J Endourol; 2024 May; 38(5):450-457. PubMed ID: 38420656
[No Abstract] [Full Text] [Related]
12. Ultrasound image segmentation of renal tumors based on UNet++ with fusion of multiscale residuals and dual attention.
Qi H; Wang Z; Qi X; Shi Y; Xie T
Phys Med Biol; 2024 Mar; 69(7):. PubMed ID: 38412532
[No Abstract] [Full Text] [Related]
13. Post Operative Complications Of Open Partial Nephrectomy With Respect To Tumour Location.
Shahzad M; Jamil MN; Ashraf H; Shafique RA; Thaimur MF; Islam EU
J Ayub Med Coll Abbottabad; 2023; 35(3):466-470. PubMed ID: 38404094
[TBL] [Abstract] [Full Text] [Related]
14. Cytokine Signaling in Pediatric kidney Tumor Cell Lines WT-CLS1, WT-3ab and G-401.
Fasler-Kan E; Milošević M; Ruggiero S; Aliu N; Cholewa D; Häcker FM; Dekany G; Bartenstein A; Berger SM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396958
[TBL] [Abstract] [Full Text] [Related]
15. Survival assessment of nephron-sparing surgery or radical nephrectomy in children with unilateral Wilms tumor receiving adjuvant chemotherapy: a retrospective cross-sectional study.
Wu XW; Zhou PP; Dong Q
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1095-1102. PubMed ID: 38375715
[TBL] [Abstract] [Full Text] [Related]
16. Long-term outcomes and potential predictive recurrence factors after endonasal endoscopic surgical treatment of symptomatic Rathke's cleft cysts.
Nakase K; Nishimura F; Yokoyama S; Kakutani M; Morisaki Y; Kotsugi M; Takeshima Y; Matsuda R; Young-Soo P; Nakagawa I
Neurosurg Rev; 2024 Feb; 47(1):85. PubMed ID: 38366128
[TBL] [Abstract] [Full Text] [Related]
17. Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched study.
Siech C; Incesu RB; Morra S; Scheipner L; Baudo A; Jannello LMI; de Angelis M; Goyal JA; Tian Z; Saad F; Shariat SF; Tilki D; Longo N; Carmignani L; de Cobelli O; Ahyai S; Briganti A; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Surg Oncol; 2024 Apr; 53():102047. PubMed ID: 38359547
[TBL] [Abstract] [Full Text] [Related]
18. Robotic transperitoneal versus retroperitoneal approach for anterior renal mass nephron-sparing surgery.
Lanzotti NJ; Felice M; Janakiraman S; Lewer O; James C; Ellis JL; Rac G; Patel HD; Gupta GN
J Robot Surg; 2024 Feb; 18(1):75. PubMed ID: 38353825
[TBL] [Abstract] [Full Text] [Related]
19. kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.
Yazdian Anari P; Zahergivar A; Gopal N; Chaurasia A; Lay N; Ball MW; Turkbey B; Turkbey E; Jones EC; Linehan WM; Malayeri AA
Abdom Radiol (NY); 2024 Apr; 49(4):1202-1209. PubMed ID: 38347265
[TBL] [Abstract] [Full Text] [Related]
20. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract] [Full Text] [Related]
[Next]
